July 2, 2009
Current Status of the Development Programs of New Indications and…
TOKYO and WOODCLIFF LAKE, N.J., July 2 /PRNewswire/ — Eisai Co., Ltd. and Eisai Corporation of North America are currently focusing on three clinical development programs for the company's major product Aricept to further contribute to patients with Alzheimer's disease.
More: continued here
Powered by FireStats
Leave a Comment
You must be logged in to post a comment.